[MDR-reversing effect of short peptide binding specifically to multidrug-resistant gastric cancer cells]

Peng Wang1, Jie Ding, Tao Lin

  • 1State Key Laboratory of Biology and PLA Institute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.

Abstract

Insights

The short peptide SY1 specifically binds to multidrug-resistant gastric cancer cells. SY1 enhances chemotherapy sensitivity and drug accumulation, offering a new approach to overcome gastric cancer drug resistance.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Context:

  • Gastric cancer remains a significant global health challenge.
  • Multidrug resistance (MDR) in gastric cancer limits the efficacy of conventional chemotherapy.
  • Novel therapeutic strategies are needed to overcome MDR in gastric cancer.

Purpose:

  • To investigate the specific binding of the short peptide SY1 to multidrug-resistant gastric cancer cells (SGC7901/VCR).
  • To evaluate the effect of SY1 on reversing drug resistance in SGC7901/VCR cells.
  • To assess SY1's impact on the accumulation of chemotherapeutic agents in resistant cells.

Summary:

  • SY1 demonstrated specific binding to the surface of SGC7901/VCR cells, not parent SGC7901 cells.
  • MTT assays revealed that SY1 significantly reduced the survival rate of SGC7901/VCR cells, enhancing sensitivity to vincristine (VCR).
  • Flow cytometry confirmed that SY1 increased the intracellular accumulation of adriamycin (ADM) in SGC7901/VCR cells.

Impact:

  • SY1 exhibits specific targeting capabilities for multidrug-resistant gastric cancer cells.
  • SY1 shows potential in reversing drug resistance and improving the effectiveness of existing chemotherapies.
  • These findings may pave the way for novel therapeutic strategies against gastric cancer MDR.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...